Hypertrophic Scar Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Hypertrophic Scar Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A7247
Buy Now

Market Overview:

The 7 major hypertrophic scar markets reached a value of US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 6.51% during 2024-2034.

Report Attribute
Key Statistics
Base Year 
2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 1.6 Billion
Market Forecast in 2034
US$ 3.3 Billion
Market Growth Rate (2024-2034)
6.51%


The hypertrophic scar market has been comprehensively analyzed in IMARC's new report titled "Hypertrophic Scar Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". A hypertrophic scar refers to a cutaneous condition in which raised, thickened, and wider scars occur around a healing wound due to an abnormal response to an injury or trauma. These scars are characterized by dermal tissue proliferation, prolonged over-deposition of extracellular matrix (ECM) proteins, particularly collagen, as well as persistent inflammation and fibrosis. The condition becomes evident within weeks of the injury and is limited to the area of damaged skin. Individuals suffering from this disorder may experience hard or thickened raised tissue, along with pink to red or purple skin color over the wound site, irritation, itching, tenderness, pain, mild discomfort, etc. In some cases, when a scar develops over the skin of a joint, it might impair the joint's normal movement. The diagnosis of this ailment is mainly based on the patient's medical history and clinical features. The healthcare provider may also perform a physical examination to evaluate the affected area. Additionally, a skin biopsy is required to confirm a diagnosis if the scar continues to change or worsen.

Hypertrophic Scar Market

The increasing cases of injury or trauma to the skin, including surgical incisions, burns, cuts, abrasions, etc., are primarily driving the hypertrophic scar market. Furthermore, the rising prevalence of several associated risk factors, such as genetic predisposition, bacterial or fungal infections at the wound site, poor wound care, herpes zoster infection, chicken pox, etc., is also propelling the market growth. In addition to this, the escalating utilization of various medications, including corticosteroid and bleomycin injections, which can soften and flatten the scar and ease symptoms like itching and pain, is creating a positive outlook for the market. Moreover, the inflating usage of tension-releasing surgical techniques, such as Z-plasty and local flap methods, for patients with advanced disease conditions who have failed conservative treatments is also bolstering the market growth. Apart from this, the emerging popularity of laser therapies, since they are less painful and uncomfortable than other scar treatment options like surgical scar revision, is acting as another significant growth-inducing factor. Additionally, the widespread adoption of silicone sheets or ointments to lower scar appearance and improve skin texture in patients is expected to drive the hypertrophic scar market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the hypertrophic scar market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hypertrophic scar and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hypertrophic scar market in any manner.

Recent Developments:

  • In April 2023, OliX Pharmaceuticals, Inc. reported positive headline results from a phase 2a trial of OLX10010 for the treatment of hypertrophic scars, which met the primary observer-based endpoint at week 24 as measured by the Patient and Observer Scar Assessment Scale (POSAS).


Key Highlights:

  • The prevalence of hypertrophic scarring varies from 40% to 70% after surgery to up to 91% after burn injury, depending on the depth of the wound.
  • Adult burn patients with darker skin, female sex, burns greater than 20% of total body surface area (TBSA), and burns on the neck and upper limbs have a higher risk of developing hypertrophic scars.
  • Hypertrophic scars tend to appear in younger populations aged 11 to 30 years.
  • Hypertension may be linked to the development of hypertrophic scars and their clinical severity.


Drugs:

STP705 is a siRNA (small interfering RNA) therapeutic that is under development by Sirnaomics for the management of hypertrophic scar. The medicine targets both TGF-β1 and COX-2 genes and uses polypeptide nanoparticles (PNPs) for improved delivery.

OLX10010 is an asymmetric siRNA duplex with a cell-penetrating moiety connected to the 3' of the sense strand (cell-penetrating asymmetric siRNA, or cp-asiRNA) that targets human connective tissue growth factor (CTGF), a critical factor in the development of hypertrophic scars. OLX10010 can be administered into cells without a delivery method and inhibits CTGF expression with complementary nucleotide sequences by degrading mRNA after transcription.


Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034


Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the hypertrophic scar market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the hypertrophic scar market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs


Competitive Landscape:

This report also provides a detailed analysis of the current hypertrophic scar marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
STP705 Sirnaomics
OLX10010 OliX Pharmaceuticals


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.


Key Questions Answered in this Report:

Market Insights

  • How has the hypertrophic scar market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the hypertrophic scar market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the hypertrophic scar market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of hypertrophic scar across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of hypertrophic scar by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of hypertrophic scar by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with hypertrophic scar across the seven major markets?
  • What is the size of the hypertrophic scar patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of hypertrophic scar?
  • What will be the growth rate of patients across the seven major markets?
     

Hypertrophic Scar: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for hypertrophic scar drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hypertrophic scar market?
  • What are the key regulatory events related to the hypertrophic scar market?
  • What is the structure of clinical trial landscape by status related to the hypertrophic scar market?
  • What is the structure of clinical trial landscape by phase related to the hypertrophic scar market?
  • What is the structure of clinical trial landscape by route of administration related to the hypertrophic scar market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Hypertrophic Scar Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARATI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More
DEinternational Egypt

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

Read More